US Drug Watchdog's Now Zeros In On Making Sure Diabetics Who Used the drug Actos & Then Developed Bladder Cancer Have The Best Attorneys For The Best Compensation The US Drug Watchdog says, "There is no way you could put a price tag on diabetics, who used the diabetes drug called Actos, and then developed bladder cancer; but we intend to make certain every Actos bladder cancer victim has the absolute best attorneys, and or trial law firms working in their behalf. Actos is a member of a class of drugs known as thiazolidinediones, which have been linked to bladder cancer. Actos side effects include increased risk of congestive heart failure, and an increased risk for bladder cancer. According to the AP, "The US FDA has also issued a warning about Actos, and bladder cancer. Both Germany and France have suspended sales of Actos. The Actos suspension is effective July 11, 2011. Actos (pioglitazone), along with another diabetes drug made by Takeda Pharmaceutical, Competact, came under fire in Europe after a study revealed an increased risk for bladder cancer among diabetes patients who were taking the medication." The US Drug Watchdog says, "We want to identify any user of the diabetes drug called Actos, if they have developed bladder cancer, and we think we will need the help of family members, and loved ones to get these victims identified." For more information please call the US Drug Watchdog anytime at 866-714-6466, or contact the group via their web site at http://USDrugWatchdog.Com (PRWEB) January 27, 2012 The US Drug Watchdog is now dramatically shifting its focus on not just identifying US diabetics, who used the diabetes drug called Actos, and then developed bladder cancer; they now also want to make certain every Actos user, who has developed bladder cancer also has the best possible national caliber law firm in their corner. The group says, "We are certain some Actos users, who developed bladder cancer are already dead, and or they are permanently disabled. It is hard to even comprehend what these Actos bladder cancer victims have gone through, or what they will go through, but we think these individuals need the best possible national caliber attorneys in their corner to advance their legal claims against this drug's maker." According to the AP, "The FDA has issued a warning that Actos may be linked to an increased risk of bladder cancer. Meanwhile, both Germany and France have suspended sales of Actos. The Actos suspension is effective July 11, 2011. Actos (pioglitazone), along with another diabetes drug made by Takeda Pharmaceutical, Competact, came under fire in Europe after a study revealed an increased risk for bladder cancer among diabetes patients who were taking the medication.The US Drug Watchdog is encouraging family members, or loved ones of diabetics, who now have bladder cancer to ask if they were also using the diabetes drug called Actos, and to call them immediately, if the answer is yes, they were using Actos. For more information Actos bladder cancer victims, or their family members are encouraged to contact the US Drug Watchdog anytime at 866-714-6466. http://USDrugWatchdog.Com The US Drug Watchdog is the premier private pharmaceutical watchdog in the United States. The group says, "Tragically the Internet is loaded with misleading ads about Actos use, and bladder cancer compensation, lawsuits, or class actions. Unfortunately, most of the attorneys or law firms advertising for help with the diabetes drug called Actos, and bladder cancer are middlemen marketing law firms--not the actual trial law firms that will prosecute these cases." They say, "We want to make certain all Actos bladder cancer victims get to the actual trial law firms or attorneys that have the best record in achieving superior results for their clients--period--no middleman marketing law firms, or attorneys." For more information please contact the US Drug Watchdog anytime at 866-714-6466, or contact the group via its web site at http://USDrugWatchdog.com Case number 11cv2406 BEN BGS in the Federal District Court San Diego, CA. ###
|
© Copyright 1997-2010, Vocus PRW Holdings, LLC. |